The loss of patent protections and a shortfall in the pipeline to replace lost sales, combined with the general decline in return on research & development and sales and marketing, has left companies searching for alternative methods of delivering maximum returns to shareholders.
Many are looking to transactions such as mergers & acquisitions, divestitures, and licensing/collaborations to enhance value during these challenging times.
Recent transaction activity in the industry includes:
- Acquisition of biotech companies to help fill pipeline needs
- Acquisitions in emerging markets to diversify away from the domestic market and into growth countries
- Acquisition of specialty pharmaceutical companies to move away from the blockbuster drug model
- Acquisition of generic companies to diversify away from the branded/ethical market
- Divestiture of non-core businesses/products
- Maximising intellectual property as companies are now licensing out non-core or secondary technology or intellectual property in an effort to fund priority programmes
- In-licensing/collaborations in an effort to find their next product success
PwC can assist with transactions
We have a strong track record of working with clients across all segments of the pharmaceutical and life sciences industry. Our specialists offer a full range of services, from inception to post-deal integration. And our global network, in combination with our in-depth industry knowledge, enables us to be constantly in touch with the markets and to spot opportunities and assemble teams to execute a deal as the need arises.
Our professionals are able to help not only with the accounting and tax considerations that deals create, but with a wide range of planning and integration concerns related to operational, systems and regulatory issues.
Contact us
Partner, Platforms & Industries Leader, Consulting Lead, PwC Belgium
Tel: +32 476 44 53 92
